EFM
PVLA

E Fund Management’s Palvella Therapeutics PVLA Stock Holding History

E Fund Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$245K Sell
1,602
-233
-13% -$28.3K 0.01% 422
2026
Q1 		$229K Buy
+1,835
New +$191K 0.01% 434

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

E Fund Management's PVLA Position: Q2 2026 in Review

E Fund Management reduced its Palvella Therapeutics (PVLA) stake by 13% in Q2 2026, selling an estimated $28.3K and leaving 1,602 shares worth $245K. The position accounts for 0.01% of the portfolio, ranked #422.

E Fund Management first reported a position in PVLA in Q1 2026 and has held it in 2 quarters since. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • E Fund Management held 1,602 shares of Palvella Therapeutics worth $245K as of Q2 2026.
  • E Fund Management sold 233 Palvella Therapeutics shares in Q2 2026, an estimated $28.3K.
  • Palvella Therapeutics made up 0.01% of E Fund Management's portfolio in Q2 2026, its #422 holding.
  • E Fund Management first reported a position in Palvella Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.